Cancer Therapy News and Research

RSS

Theragenics enters second amended and restated credit agreement with Wells Fargo

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association.

11 Oct 2012

Patient navigation services help vulnerable patients get timely cancer care

Researchers at Boston Medical Center (BMC) have shown that patient navigation services help decrease the time to diagnosis for female patients who have received an abnormal result from a breast or cervical cancer screening.

10 Oct 2012

CRI, MedImmune partner to advance cancer immunotherapy research

The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer.

10 Oct 2012

New blood test can read genetic changes in prostate cancer

Scientists have designed a blood test that reads genetic changes like a barcode - and can pick out aggressive prostate cancers by their particular pattern of gene activity.

9 Oct 2012

NIH awards $2.1M grant to study possible ways to fight cancer

A professor with the University of Houston Cullen College of Engineering has won a $2.1 million grant to study the best ways to modify human immune cells to fight against cancer.

6 Oct 2012

Many breast cancer survivors insufficiently active after leaving supervised programs

More than 40 percent of older breast cancer survivors are insufficiently active after leaving a supervised program. But new research shows that those women who developed behavioral skills such as self-confidence and motivation during their program were far more likely to continue exercising on their own.

6 Oct 2012

Nelfinavir inhibits growth of HER2-positive tumors

The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute.

6 Oct 2012

New book on natural interventions for lung cancer

Told he had lung cancer and 6 months to live, the author refused chemo/surgery and used holistic, natural, non-invasive interventions. Now, 38 years later at age 80 he not only beat the odds of lung cancer but also the odds of 3 chronic illnesses and 5 prescribed medications that are the average for a 75 year old.

5 Oct 2012

Rare study highlights anal cancer prognosis risks

The presence of palpable, clinically involved inguinal lymph nodes and male gender are both independent risk factors for poor prognosis in anal cancer, confirm the results of a UK analysis.

3 Oct 2012

Adolescent and young cancer cost barriers: an interview with Anne Kirchhoff

According to the National Cancer Institute, almost 70,000 people ages 15-39 are diagnosed with cancer each year in the United States. Cancers in this adolescent and young adult (AYA) population differ quite a bit across this age span.

3 Oct 2012

Financial Times examines legal disputes in India over pharmaceutical patent laws

The Financial Times reports on a legal dispute between the Indian government and the German pharmaceutical group Bayer, writing, "Bayer is appealing against the Indian patent controller's decision in March to override the company's monopoly on its cancer drug Nexavar, and to allow an Indian company to produce and sell the life-extending drug for just $173 a month -- one-sixth of the $5,500 a month price charged by Bayer."

3 Oct 2012

CINJ database enhancements help physicians to ensure safety in chemotherapy delivery

Database enhancements developed at The Cancer Institute of New Jersey (CINJ) are helping physicians use technology to further ensure safety in the delivery of chemotherapy.

3 Oct 2012

BHGI sponsors global summit on international breast health

For women with breast cancer in low- and middle-resource countries and other medically underserved areas around the world, the need for supportive care and the consideration of quality-of-life issues are often overlooked.

2 Oct 2012

Mount Sinai surgeon offers tips to prevent prostate cancer

World-renowned Mount Sinai robotic prostate surgeon, Dr. David Samadi, devotes much of his time to prostate cancer education domestically and internationally. "My SMART robotic prostate removal surgery saves lives, but what men really want to know is how to prevent prostate cancer in the first place," shares Dr. Samadi.

29 Sep 2012

ACS honors world-leader in robotic prostate surgery with 2012 Community Partner Award

At last night's Annual Prostate Cancer Awareness and Education Dinner, the American Cancer Society awarded Dr. David B. Samadi, world-leader in prostate cancer treatment and robotic prostate surgery, with the 2012 Community Partner Award. Through robotic surgery excellence, Dr. Samadi has successfully cured more than 4,000 men of prostate cancer.

29 Sep 2012

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

The U.S. Food and Drug Administration today approved Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).

28 Sep 2012

Go Daddy donates $10,000 for Scottsdale Healthcare Cancer Center fundraiser

GoDaddy.com, the world's largest provider of Web hosting and domain name registrations, is donating $10,000 to help cancer patients and kick-start fundraising for the 4th annual Scottsdale Healthcare Rob Moy Memorial Motorcycle Run.

27 Sep 2012

Henry Ford Hospital opens new Center for Cancer Surgery

With more patients seeking cancer treatment – especially surgery – than ever before, Henry Ford Hospital has opened the new Center for Cancer Surgery.

27 Sep 2012

CTCA at Midwestern named Certified Quality Breast Center of Excellence

Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (Midwestern) has been recognized by the National Quality Measures for Breast Centers Program (NQMBC) as being among the top centers in the country for providing quality breast cancer care.

27 Sep 2012

CivaTech Oncology receives NIH/NCI Phase II Contract for CivaSheet device to treat NSCLC

CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.

26 Sep 2012